#### CLINICAL STUDY

OPEN ACCESS Check for updates

Taylor & Francis

Taylor & Francis Group

# Effect of goal-directed fluid therapy on renal function in critically ill patients: a systematic review and meta-analysis

Cong-Cong Zhao<sup>a</sup>, Yan Ye<sup>a</sup>, Zhi-Qiang Li<sup>b</sup>, Xin-Hui Wu<sup>a</sup>, Chai Zhao<sup>a\*</sup> (b) and Zhen-Jie Hu<sup>a\*</sup>

<sup>a</sup>Department of Intensive Care Unit, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China; <sup>b</sup>Department of Intensive Care Unit, North China University of Science and Technology Affiliated Hospital, Tangshan, China

#### ABSTRACT

**Objective:** To evaluate whether goal-directed fluid therapy (GDFT) reduces the risk of renal injury in critical illness.

**Methods:** MEDLINE *via* PubMed, EMBASE, CENTRAL and CBM was searched from inception to 13 March 2022, for studies comparing the effect of GDFT with usual care on renal function in critically ill patients. GDFT was defined as a protocolized intervention based on hemodynamic and/or oxygen delivery parameters. A fixed or random effects model was applied to calculate the pooled odds ratio (OR) based on heterogeneity through the included studies.

**Results:** A total of 28 studies with 9,019 patients were included. The pooled data showed that compared with usual care, GDFT reduced the incidence of acute kidney injury (AKI) in critical illness (OR 0.62, 95% confidence interval (CI) 0.47 to 0.80, p < 0.001). Sensitivity analysis with only low risk of bias studies showed the same result. Subgroup analyses found that GDFT was associated with a lower AKI incidence in both postoperative and medical patients. The reduction was significant in GDFT aimed at dynamic indicators. However, no significant difference was found between groups in RRT support (OR 0.88, 95% CI 0.74 to 1.05, p = 0.17). GDFT tended to increase fluid administration within the first 6 h, decrease fluid administration after 24 h, and was associated with more vasopressor requirements.

**Conclusions:** This meta-analysis suggests that GDFT aimed at dynamic indicators may be an effective way to prevent AKI in critical illness. This may indicate a benefit from early adequate fluid resuscitation and the combined effect of vasopressors.

#### Introduction

Acute kidney injury (AKI) is a clinical syndrome due to an abrupt decrease in kidney function and is typically diagnosed by increased creatinine, decreased urine output, or both [1]. It is a common and serious complication in critically ill patients and is associated with increases in hospitalization cost, morbidity, and mortality [2,3]. It should be noted that just with the occurrence of AKI, short- and long-term survival will be significantly reduced for patients with AKI regardless of its severity and evolution [4]. Therefore, the prevention of AKI is crucial in critically ill patients.

AKI prevention is a multimodal clinical algorithm based on protocolized volume status and perfusion pressure optimization [5], which require adequate renal blood flow. Unfortunately, routine hemodynamic measurements, such as the mean blood pressure (MAP) and central venous pressure (CVP), are poor predictors of volume status and renal blood flow in critical illness. The end points of fluid resuscitation are uncertain and challenging, which leads to the development of protocolized hemodynamic resuscitation. This goal-directed fluid therapy (GDFT) approach uses intensive monitoring, including some measures of hemodynamics (such as MAP, CVP, cardiac output (CO), and stroke volume (SV)) and oxygen delivery parameters (such as oxygen delivery, central venous oxygenation (ScvO<sub>2</sub>) or mixed venous oxygenation).

GDFT reduced the risk of perioperative complications [6,7], including renal injury [8]. A recent meta-analysis found that GDFT improved renal perfusion and oxygenation in high-risk patients undergoing major abdominal

CONTACT Chai Zhao 🐼 1481529762@qq.com 🗈 The Fourth Affiliated Hospital of Hebei Medical University, Intensive Care Unit, 12 Jiankang Road, Shijiazhuang, 050011 China

\*These authors contributed equally to this work.

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

#### **ARTICLE HISTORY**

Received 5 January 2022 Revised 23 March 2022 Accepted 24 April 2022

#### **KEYWORDS**

Acute kidney injury; fluid therapy; critical care; systematic review; meta-analysis

Supplemental data for this article can be accessed https://doi.org/10.1080/0886022X.2022.2072338.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

and orthopedic surgery [9]. In addition, previous studies have suggested that GDFT is associated with a decrease in AKI incidence in critical illness [10–12]. However, some studies found no beneficial effect of GDFT on renal function [13–15]. Furthermore, different kinds of patients, protocolized goals, and study designs make it difficult to provide specific recommendations for GDFT.

Hence, this meta-analysis aimed to evaluate the effects of GDFT on renal function in critically ill patients. In particular, we tried to clarify which protocolized goals are effective, what kinds of patients can benefit from them, and the roles of fluids and vasopressors in this approach.

# **Methods**

# Protocol and registration

This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [16]. The protocol of this work was registered in the PROSPERO database (CRD42021233518).

## Search strategy

We searched the MEDLINE *via* PubMed, EMBASE, CENTRAL and CBM databases (from inception to 13 March 2022) using the terms: ("intensive care" or "emergency" or "critical illness") AND ("fluid resuscitation" or "fluid therapy") AND ("goal-directed" or "goal-oriented" or "target-directed"). There were no language limits on eligibility. The Supplementary Material 1 shows the search strategy in more detail.

# **Study selection**

Two investigators (CCZ, YY) independently determined whether eligible studies met the following PICOS criteria: 1) Population: adult patients (age >18 years) treated at an intensive care unit or emergency department; 2) Intervention: protocolized and based on hemodynamic and oxygen delivery parameters; 3) Control: usual care, defined as conventional treatments that were at the discretion of the clinicians. Monitoring by CVP or MAP measurements was allowed. 4) Outcomes: The primary outcome was the incidence of AKI at any time point during hospitalization, whichever definition of AKI was adopted. Secondary outcomes were renal replacement therapy (RRT) support, fluid administration, and vasopressor requirements. 5) Type of studies: randomized controlled trials (RCTs), quasi-RCTs, and prospective and retrospective controlled trials.

The exclusion criteria were as follows: 1) lack of a protocolized intervention; 2) lack of a baseline condition or control group; 3) lack of data on any renal outcome: AKI and RRT; and 4) no original studies, case reports, case series, animal studies, *in vitro* studies, and studies without full text.

# **Data extraction**

The initial and full-text reviews and data extraction from the included studies were performed independently by two authors (CCZ, YY). The kappa coefficient was calculated as a measure of agreement about study selection and quality appraisal. Any discrepancies were resolved by the third author (ZQL), and a decision was reached by consensus.

Data were collected using a predesigned form. For each study, the following information was extracted: publication (last name of the first author, year of publication), participant characteristics (including patient source, diagnosis, demographic data, clinical setting, and number of patients), targets used in the GDFT protocol (including MAP, CVP, CO/CI, SV, stroke volume variation (SVV), pulse pressure variation (PPV), oxygen delivery parameters *et al.*), study design, and outcome data.

#### Assessment of risk of bias

Two authors (CCZ, YY) independently assessed the risk of bias to evaluate the quality of the included studies. The Cochrane Collaboration tool [17] was used for RCTs, and the ROBINS-I tool (Risk of Bias in Nonrandomized Studies of Interventions) [18] was used for non-RCTs. Funnel plot was used to evaluate publication bias.

#### Statistical analysis

SPSS 25.0 was used to calculate the kappa coefficient. Data analysis was conducted using RevMan 5.3. The results are presented as forest plots using odds ratios (ORs) for dichotomous data and the mean difference (MD) for continuous data. All estimates were provided with 95% confidence intervals (CIs). Heterogeneity was assessed by Cochran's Q statistic and the  $I^2$  test. A *P* value >0.1 or  $I^2$  statistic below 50% indicated low levels of heterogeneity. In these cases, a fixed-effect model was used. Otherwise, a random-effects model (Mantel-Haenszel method) was selected. Sensitivity analysis with only low risk of bias studies was considered if the pooled data of the primary outcome had



Figure 1. Study selection flow diagram according to the PRISMA guidelines.

significant heterogeneity. Several subgroup analyses were performed for the primary outcome according to population (postoperative and medical patients), GDFT protocol (early goal-directed therapy (EGDT) [11], dynamic indicators (defined as the variation of certain indicators in the GDFT protocol), and other protocols), and the design of the trial (RCT and non-RCT). p< 0.05 indicated statistical significance.

#### Results

The search strategy identified 1,768 unique publications, and 2 additional records were identified from reference lists. After excluding duplicates (n = 258) and screening titles and abstracts (n = 1,512), 111 studies were assessed in full text for eligibility (Figure 1). Following full-text review, a total of 28 studies met the inclusion criteria (kappa = 0.858, p < 0.01). Among these, three studies were reported in Chinese [19–21], and all the other studies were reported in English [10,14,22–44].

The characteristics of the included studies are summarized in Table 1. In total, the included studies comprised 9,019 patients, and the number of patients per study was 48 to 1,591. Of the 28 included studies, 21 studies were RCTs, and the other seven were not. The risk of bias assessments for RCTs and non-RCTs are shown in Figure 2 (kappa = 0.766, p< 0.01). The green, red and yellow colors indicate a low risk of bias, a high risk of bias, and an unclear risk of bias, respectively. Studies with more than or equal to five green plus were considered low risk of bias studies. Among the 28 included studies, all except for five studies [27,28,38,40,42] had a low risk of bias overall.

Studies	Country	Design	Department	Population	No. of patients (GDFT vs. Control)	GDFT proposal	Control	Outcomes
McKendry et al.2004 [32]	United Kingdom	RCT	Surgical ICU	post-surgery	174 (89 vs. 85)	SVI >35 ml/m <sup>2</sup> & increase	usual care	AKI, fluids administration
Lin et al. 2006 [10]	China	RCT	Medical ICU	septic shock	224 (108 vs. 116)	<pre> &lt; 10% after fluid challenge EGDT without ScvO2</pre>	usual care	AKI, fluids administration,
Jhanji et al. 2010 [26]	United Kingdom	RCT	ICU	post-surgery	90 (45 vs. 45)	SV increase <10% after	CVP rise ≥2 mmHg	vasopressor requirement AKI, fluids administration,
Goepfert et al.2013 [24]	Germany	RCT	ICU	post-surgery	92(46 vs. 46)	fluid challenge SVV $\leq 10\%$	CVP > 8  or	vasopressor requirement AKI, fluids administration
Kanji et al. 2014 [27]	Canada	prospective before-after	ICU	undifferentiated shock	220(110 vs. 110)	IVC collapsibility $< 15\%$	MAP > 65 mmHg CVP 8–12 mmHg	AKI, vasopressor requirement
Peake et al. 2014 [25]	Australia & New Zealand	study RCT	Emergency department	early septic shock	1591(793 vs. 798)	EGDT	usual care	RRT, fluids administration, vasonrescor requirement
Pearse et al. 2014 [36]	United Kingdom	RCT	ICU	post-surgery	734 (368 vs 366)	CO-guided hemodynamic	usual care	AKI, fluids administration,
Pestaña et al. 2014 [37]	Spain	RCT	ICU	post-surgery	142 (72 vs. 70)	titierapy aigonumi MAP ≥65 mmHg & Cl > 3 51 /min/m²	usual care	AKI, fluids administration,
Suzuki et al. 2014 [39]	Australia	prospective before-after	ICU	post-surgery	98 (53 vs. 45)	PPV < 13%	usual care	AKI, fluids administration
Thomson et al. 2014 [40]	United Kingdom	prospective prospective	Cardiothorac-ic ICU	post-surgery	264 (123 vs. 141)	SV increase <10% after finid challance	standard therapy	AKI, RRT, fluide administration
Yealy et al. 2014 [14]	United States	RCT	Emergency department	septic shock	895 (439 vs. 456)	EGDT	usual care	AKI, RRT, fluids administration,
Mouncey et al. 2015 [33]	United Kingdom	RCT	Emergency department	early septic shock	1251 (625 vs. 626)	EGDT	usual care	vasopressor requirement RRT, fluids administration, vasopressor requirement
Liu et al. 2016 [19]	China	prospective before-after study	ICU	Moderate brain injury& traumatic shock	98 (48 vs. 50)	EGDT	usual care	AKI, fluids administration
Jin et al. 2016 [22]	China	retrospective before-after study	ICU	post-surgery	232 (131 vs. 101)	CVP 10-12 mmHg; CI ≥ 2.4 L/min/m²; lactate <4 mmol/L; Sv/O. > 65%	MAP 65-100 mmHg	AKI, fluids administration
Schmid et al. 2016 [38]	Germany	RCT	ICU	post-surgery	180 (92 vs. 88)	MAP >70 mMAP, Cl >2.5 L/min/m <sup>2</sup> ; GEDI >800 mL/m <sup>2</sup> ; ELWI	usual care	AKI, RRT, fluids administration
Latham et al. 2017 [28]	United States	retrospective	Medical or	post-surgery	191 (100 vs. 91)	<ul> <li>&lt;10 mi/kg</li> <li>SVI increased &lt;10% after</li> <li>4</li></ul>	usual care	RRT
Luo et al. 2017 [29]	China	conort stuay RCT	Iransplant Icus ICU	severe sepsis &septic shock	145 (73 vs. 72)	nuid chailenge Cl >2.5 L/min/m <sup>2</sup> , SVV <15%	usual care	AKI, RRT, fluids administration,
Yu et al. 2017 [41] Huang et al. 2018 [20]	China China	RCT	ICU	COPD with septic shock hypovolemic shock	71 (34 vs. 37) 48 (25 vs. 23)	GEDI ≥800mL/m <sup>2</sup> EGDT	usual care CVP 8–12 mmHg	vasopressor requirement RRT, fluids administration, AKI, fluids administration,
MacDonad et al. 2019 [30]	United Kingdom	RCT	ICU	post-surgery	287 (144 vs. 143)	CO-guided hemodynamic	usual care	vasopressor requirement AKI
Pan et al. 2019 [21]	China		ICU	post-surgery	171 (103 vs. 68)			AKI, RRT
								(continued)

Table 1. Characteristics of studies included in this meta-analysis.

Table 1. Continued.

Studies	Country	Design	Department	Population	No. of patients (GDFT vs. Control)	GDFT proposal	Control	Outcomes
		prospective cohort study				CI > 2.5 L/min/m <sup>2</sup> /GEDVI >700 mL/m <sup>2</sup> or ITBVI > 850 mL/m <sup>2</sup> ; EVLWI < 10 mL/kg; MAP > 65 mmHa	CVP8-10, MAP > 65 mmHg	
Douglas et al. 2020 [23]	United States & United Kingdom	RCT	Emergency department & ICU	sepsis or septic shock	150 (102 vs 48)	SV increase <10% after passive leg raise	usual care	RRT
Martin et al. 2020 [31]	United Kingdom	RCT	ICU	post-surgery	60 (30 vs. 30)	SVV <10%	usual care	RRT, fluids administration אנו מסד
יסן בטבו ניי			department	septic stock	(101 .64 101) 022	INC CONAPSIONINY < 40% (non-MV) or IVC distensibility <18% (MV)	ubual care	fluids administration, vasopressor requirement
Parke et al. 2021 [35]	Australian & New Zealand	RCT	Surgical ICU	post-surgery	715 (358 vs. 357)	CI >2.5 L/min/m <sup>2</sup> , SVV <13%	usual care	AKI, RRT, fluids administration,
Waal et al. 2021 [42]	China	RCT	Surgical ICU	post-surgery	482 (234 vs. 248)	age-dependent target for CI & SVV and PLR	usual care	vasopressor requirement AKI
Wang et al. 2021 [43]	Netherlands	RCT	Pacu /Icu	post-surgery	134 (66 vs. 68)	Bioelectrical impedance analysis	usual care	AKI, fluids administration
Froghi et al. 2022 [44]	United Kingdom	RCT	ICU	post-surgery	60 (30 vs. 30)	SV rise $\leq$ 10%, SV drop $\leq$ 10%	usual care	AKI, fluids administration
AKI: acute kidney injury; CC	): cardiac output; Cl:	cardiac index; CC	DD: chronic obstru-	ctive pulmonary disease; CV	P: central venous press	sure; EGDT: early goal directe	d therapy; EVLWI extr	avascular lung water index;

ICU: intensive care unit; IVC: Inferior Vena Cava; GDFT: goal-directed fluid therapy; GEDI Global end-diastolic index; MAP: mean blood pressure; MV mechanical ventilation; No. : number; PACU: Post-Anesthesia Care units; PLR: passive leg raising; PV: pulse pressure variation; RCT: randomized controlled trial; RRT: renal replacement therapy; ScvO<sub>2</sub>: central venous oxygenation; SvO<sub>2</sub>: mixed venous oxygenation; SV: stroke volume; SVI: stroke volume index.



**Figure 2.** Risk of bias summary assessments for included studies.

# **Incidence of AKI**

Twenty-two (n = 5,649, 2,853 in the GDFT group and 2,796 in the control group) of the 28 included studies reported that the incidence of AKI ranged from 0%–95% with different follow-up times. All but six of the included studies reported a clear definition of AKI. The incidence of AKI was lower in postoperative patients and higher in medical patients. The detailed parameters of AKI, including the morbidity, definition,

and follow-up time in each study, are shown in Supplementary Table 1. The pooled data showed that GDFT significantly reduced AKI incidence over usual care (OR 0.62, 95% CI 0.47 to 0.80, p < 0.001; Figure 3). The heterogeneity was moderate ( $l^2=50\%$ ). No sign of significant publication bias was observed (Supplementary Figure 1). The sensitivity analysis considering only low risk of bias studies showed the same result: compared with usual care, GDFT reduced the risk of renal injury in critically ill patients (OR 0.66, 95% CI 0.54 to 0.82, p < 0.001;  $l^2=13\%$ ).

Subgroup analyses showed that in both postoperative and medical patients, the AKI incidences were lower in the GDFT group (postoperative patients: OR 0.68, 95% CI 0.54 to 0.87, p= 0.002; medical patients: OR 0.39, 95% CI 0.17 to 0.86, p = 0.02; Figure 4). The heterogeneity was low in the subgroup of postoperative patients ( $l^2=27\%$ ) but higher in the subgroup of medical patients ( $I^2 = 70\%$ ). In medical patients, we further performed a subgroup analysis of patients with septic shock, which showed no effect of GDFT on AKI with a lower heterogeneity (OR 0.66, 95% CI 0.39 to 1.14, p = 0.14;  $l^2 = 22\%$ ). A significant AKI reduction was observed in studies that adopted dynamic indicators (including SVV, PPV, SV change, IVC collapsibility and distensibility) as fluid therapy targets (OR 0.48, 95% CI 0.30 to 0.77, p = 0.002;  $l^2 = 58\%$ ; Figure 5), instead of these studies with EGDT (OR 0.55, 95% CI 0.25 to 1.24, p= 0.15; l<sup>2</sup>=62%; Figure 5) or the other protocols (OR 0.74, 95% CI 0.53 to 1.01, p = 0.06;  $l^2 = 25\%$ ; Figure 5). In addition, the pooled data from RCTs (OR 0.78, 95% CI 0.65 to 0.95, p = 0.01;  $I^2 = 12\%$ ; Figure 6) and non-RCTs (OR 0.37, 95% CI 0.27 to 0.51, *p*< 0.001; l<sup>2</sup>=47%; Figure 6) both showed a preventive effect of GDFT on AKI in critically ill patients.

#### **RRT** support

Thirteen (n = 5,709, 2,884 in the GDFT group and 2,825 in the control group) of the 28 included studies reported pooled analysis showing GDFT did not decrease the requirement for RRT (OR 0.88, 95% CI 0.74 to 1.05, p = 0.17;  $l^2 = 50\%$ ; Supplementary Figure 2) in critically ill patients.

#### Fluid administration (L)

Of the 28 included studies, 22 (n = 11,965, 5,983 in the GDFT group and 5,982 in the control group) reported intravenous fluids at different time points. According to the different record times of fluid administration, the 22 studies were divided into three subgroups: within the

	GDF	т	Conti	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Froghi 2022	16	30	16	30	4.2%	1.00 [0.36, 2.76]	
Goepfert 2013	3	46	8	46	2.7%	0.33 [0.08, 1.34]	
Huang 2018	3	25	10	23	2.5%	0.18 [0.04, 0.76]	
Jhanji 2010	3	45	10	45	2.8%	0.25 [0.06, 0.98]	
Jin 2016	32	131	38	101	7.4%	0.54 [0.30, 0.94]	
Kanji 2014	65	95	88	93	4.3%	0.12 [0.05, 0.33]	
Lin 2006	42	108	64	116	7.7%	0.52 [0.30, 0.88]	
Liu 2016	0	48	0	50		Not estimable	
Luo 2017	3	73	6	72	2.6%	0.47 [0.11, 1.96]	
MacDonald 2019	9	144	11	143	4.8%	0.80 [0.32, 1.99]	
McKendry 2004	1	89	3	85	1.2%	0.31 [0.03, 3.05]	· · · · ·
Musikatavorn 2021	4	101	2	101	1.9%	2.04 [0.37, 11.40]	
Pan 2019	50	103	47	68	6.7%	0.42 [0.22, 0.80]	
Parke 2021	96	358	105	357	9.6%	0.88 [0.63, 1.22]	
Pearse 2014	17	366	17	364	6.3%	0.99 [0.50, 1.98]	
Pestaña 2014	8	72	9	70	4.2%	0.85 [0.31, 2.34]	
Schmid 2016	53	92	46	88	7.2%	1.24 [0.69, 2.23]	
Suzuki 2014	9	53	12	45	4.4%	0.56 [0.21, 1.49]	
Thomson 2014	8	123	28	141	5.3%	0.28 [0.12, 0.64]	
Waal 2021	12	246	10	234	5.1%	1.15 [0.49, 2.71]	
Wang 2021	6	66	9	68	3.8%	0.66 [0.22, 1.96]	
Yealy 2014	12	439	11	456	5.3%	1.14 [0.50, 2.60]	
							•
Total (95% CI)		2853		2796	100.0%	0.62 [0.47, 0.80]	•
Total events	452		550				
Heterogeneity: Tau <sup>2</sup> =	0.16; Chi <sup>2</sup>	= 39.6	5, df = 20	(P = 0	.006); l² =	50%	
Test for overall effect: 2	Z = 3.63 (F	<b>&gt;</b> = 0.0	003)				Eavours [GDET] Eavours [control]

Figure 3. Forest plot of the effect of GDFT on AKI incidence without time limit. AKI: Acute kidney injury; GDFT: goal-directed fluid therapy; M-H: Mantel–Haenszel; CI: confidence interval.

initial 6 h, more than 6 h and less than or equal to 24 h, and more than 24 h. The pooled data from 9 studies (n = 5,058; 2,526 in the GDFT group and 2,532 in thecontrol group) showed that GDFT tended to increase the volume of fluid administration within the initial 6 h, but there was no significant difference between groups (MD 0.27, 95% CI -0.04 to 0.59, p= 0.09; Supplementary Figure 3). The heterogeneity was high. The pooled data from 13 studies (n = 2,261; 1,141 in the GDFT group and 1,120 in the control group) showed that GDFT had no effect on fluid administration from 6 to 24 h (MD 0.34, 95% CI -0.14 to 0.81, p= 0.16; I<sup>2</sup>=98%; Supplementary Figure 3). However, the cumulative fluid administration in the GDFT group was less than that in the control group after 24 h (n = 4,646; 2,316 in the GDFT group and 2,330 in the control group), with high heterogeneity (MD -0.45, 95% CI -0.71 to -0.19, p < 0.001;  $l^2 = 90\%$ ; Supplementary Figure 3).

#### Vasopressor requirements

For this outcome, 12 studies reported the use of vasopressors (n = 6,252; 3,116 in the GDFT group and 3,136 in the control group). Compared with the control group, patients in the GDFT group seemed to use more vasopressors, but the difference was not significant (OR 1.23, 95% CI 1.00 to 1.52, p= 0.05;  $l^2=58\%$ ; Supplementary Figure 4).

# Discussion

This systematic review is the first to focus on the effect of GDFT on renal function in critically ill patients. Pooled data demonstrated that the incidence of AKI was reduced by GDFT in critical illness. This result was confirmed by the sensitivity analysis enrolling only lowrisk-of-bias trials and the pooled data from RCTs. Subgroup analyses showed that both postoperative and medical patients benefited from GDFT, and the reduction in AKI was significant in GDFT aimed at dynamic indicators. However, GDFT was not associated with a reduction in RRT support.

Critically ill patients are at high risk of AKI, which is closely associated with poor prognosis. The most frequent causes of AKI in critical illness are sepsis, hypovolemia, direct nephrotoxicity, and major surgery [45]. AKI is believed to be initially preventable and reversible [46]. Fluid therapy is a key component of the prevention of AKI, and the aim is to correct hypovolemia and restore organ perfusion in addition to avoiding further nephrotoxic insults. Because routine hemodynamic measurements poorly predict volume status and renal



Figure 4. Pooled AKI incidence of subgroup analysis concerning postoperative and medical patients. AKI: Acute kidney injury; M-H: Mantel-Haenszel; CI: confidence interval.

blood flow in critical illness, the GDFT approach has been proposed.

Our study found that in comparison with usual care, GDFT reduced the incidence of AKI in critically ill patients. However, moderate heterogeneity limits the credibility of the results. Several questions remain unanswered, such as kind of patients, protocolized goals, and the impact of the quality of included studies. Therefore, we first performed sensitivity analysis enrolling only low-risk-of-bias trials. This showed the same result with low heterogeneity. Then, subgroup analysis of RCTs further confirmed the main result. In addition, subgroup analyses concerning postoperative versus medical patients and different fluid therapy targets were also performed.

The subgroup analysis of populations showed that GDFT significantly reduced AKI in both postoperative

and medical patients. Consistently, a recent meta-analysis, including 65 studies with 9,306 adult patients undergoing major surgery and noncritical illness, which reported a marked decrease in the renal injury rate in the perioperative goal-directed therapy group [9]. It is worth noting that we found the preventive effect on AKI in medical patients. In fact, only six included study populations were medical patients. They were all shock patients, and half of them had septic shock. A further subgroup analysis of patients with septic shock showed no effect of GDFT on AKI. Similarly, a previous multicenter large sample RCT did not find any protective effect of EGDT on renal function in septic shock patients [14]. In patients/animals with septic shock, global renal blood flow is preserved or even increased [47]. In contrast, decreases in glomerular filtration pressure, inflammatory tubules and microvascular injury result in renal

	GDF	г	Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight M	-H, Random, 95% CI	M-H, Random, 95% CI
1.5.1 EGDT							
Huang 2018	3	25	10	23	2.4%	0.18 [0.04, 0.76]	
Lin 2006	42	108	64	116	7.8%	0.52 [0.30, 0.88]	
Liu 2016	0	48	0	50		Not estimable	
Yealy 2014	12	439	11	456	5.3%	1.14 [0.50, 2.60]	
Subtotal (95% CI)		620		645	15.5%	0.55 [0.25, 1.24]	
Total events	57		85				
Heterogeneity: Tau <sup>2</sup> = 0	0.31; Chi <sup>2</sup>	= 5.24	, df = 2 (F	9 = 0.07	′); I² = 62%		
Test for overall effect: 2	Z = 1.44 (F	<b>P</b> = 0.1	5)				
1.5.2 dynamic indicat	ors						
Froghi 2022	16	30	16	30	4.2%	1.00 [0.36, 2.76]	
Goepfert 2013	3	46	8	46	2.6%	0.33 [0.08, 1.34]	· · · · ·
Jhanji 2010	3	45	10	45	2.7%	0.25 [0.06, 0.98]	
Kanji 2014	65	95	88	93	4.2%	0.12 [0.05, 0.33]	
Luo 2017	3	73	6	72	2.5%	0.47 [0.11, 1.96]	
McKendry 2004	1	89	3	85	1.1%	0.31 [0.03, 3.05]	
Musikatavorn 2021	2	101	4	101	1.9%	0.49 [0.09, 2.74]	
Parke 2021	96	358	105	357	9.9%	0.88 [0.63, 1.22]	
Suzuki 2014	9	53	12	45	4.4%	0.56 [0.21, 1.49]	
Thomson 2014	8	123	28	141	5.3%	0.28 [0.12, 0.64]	
Waal 2021	12	246	10	234	5.1%	1.15 [0.49, 2.71]	
Subtotal (95% CI)		1259		1249	43.9%	0.48 [0.30, 0.77]	$\bullet$
Total events	218		290				
Heterogeneity: Tau <sup>2</sup> = 0	0.31; Chi <sup>2</sup>	= 24.0	3, df = 10	(P = 0	.008); l <sup>2</sup> = 589	%	
Test for overall effect: 2	Z = 3.05 (F	<b>P</b> = 0.0	02)				
1.5.3 other protocols							
Jin 2016	32	131	38	101	7.5%	0.54 [0.30, 0.94]	
MacDonald 2019	9	144	11	143	4.7%	0.80 [0.32, 1.99]	
Pan 2019	50	103	47	68	6.8%	0.42 [0.22, 0.80]	
Pearse 2014	17	366	17	364	6.4%	0.99 [0.50, 1.98]	
Pestaña 2014	8	72	9	70	4.1%	0.85 [0.31, 2.34]	
Schmid 2016	53	92	46	88	7.3%	1.24 [0.69, 2.23]	
Wang 2021	6	66	9	68	3.8%	0.66 [0.22, 1.96]	
Subtotal (95% CI)		974		902	40.5%	0.74 [0.53, 1.01]	$\bullet$
Total events	175		177				
Heterogeneity: Tau <sup>2</sup> = 0	0.05; Chi <sup>2</sup>	= 8.00	, df = 6 (P	= 0.24	); l² = 25%		
Test for overall effect: 2	Z = 1.87 (F	<b>P</b> = 0.0	6)				
		2052		2700	100.00/	0 60 10 46 0 701	
Total (95% CI)	150	2853		2/90	100.0%	0.60 [0.46, 0.78]	•
I otal events	450	00.1	552	(D )	000) 12 (2)		
Heterogeneity: $Iau^2 = 0$	0.15; Chi <sup>2</sup>	= 38.1	b, df = 20	(P = 0	.008); I <sup>2</sup> = 489	%	0.05 0.2 1 5 20
lest for overall effect: 2	∠ = 3.89 (F	- = 0.0	001)	-			Favours [experimental] Favours [control]
l est for subaroup diffe	rences: Ch	nı² = 2.:	25. dt = 2	(P = 0)	$(32)$ , $I^2 = 11.2$	%	

Figure 5. Pooled AKI incidence of subgroup analysis concerning different GDFT protocols, including EGDT, dynamic indicators and other protocols. AKI: Acute kidney injury; GDFT: goal-directed fluid therapy; EGDT: early goal directed therapy; M-H: Mantel–Haenszel; CI: confidence interval.

dysfunction in sepsis [48]. Therefore, optimizing hemodynamics has limited preventive effects on septic AKI.

The subgroup analysis regarding targets showed that GDFT based on dynamic indicators significantly reduced AKI incidence, rather than EGDT and other protocols. However, the heterogeneity in the 'dynamic indicators' subgroup was relatively high and two large studies [27,40] which showed preferable results for GDFT in this subgroup were non-RCTs. These can be a risk of bias and weak the strength of the evidence. About EGDT, it was first introduced by Rivers *et al* and mainly used in patients with sepsis [11]. The effect of EGDT on prognosis, including AKI and mortality, is still

controversial [10,14,25,33]. In summary, GDFT aimed at dynamic indicators may be an effective way to protect renal function in critically ill patients.

In addition, there was no effect of GDFT on RRT support. Consistently, a previous meta-analysis found no differences in the RRT rate between the standard EGDT and usual care groups in patients with severe sepsis and septic shock [49]. These results suggested that GDFT did not improve the deterioration of renal function in patients who had already developed AKI. Consistent with this view, one previous study reported that GDFT did not reduce the persistence of AKI beyond 72 h for patients in the early stage of AKI [15]. In

	GDFT		Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events 1	<b>Fotal</b>	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
1.6.1 RCTs							
Froghi 2022	16	30	16	30	2.0%	1.00 [0.36, 2.76]	
Goepfert 2013	3	46	8	46	2.0%	0.33 [0.08, 1.34]	
Huang 2018	3	25	10	23	2.5%	0.18 [0.04, 0.76]	
Jhanji 2010	3	45	10	45	2.5%	0.25 [0.06, 0.98]	
Lin 2006	42	108	64	116	10.2%	0.52 [0.30, 0.88]	
Luo 2017	3	73	6	72	1.6%	0.47 [0.11, 1.96]	
MacDonald 2019	9	144	11	143	2.8%	0.80 [0.32, 1.99]	
McKendry 2004	1	89	3	85	0.8%	0.31 [0.03, 3.05]	
Musikatavorn 2021	2	101	4	101	1.1%	0.49 [0.09, 2.74]	
Parke 2021	96	358	105	357	20.9%	0.88 [0.63, 1.22]	
Pearse 2014	17	366	17	364	4.4%	0.99 [0.50, 1.98]	
Pestaña 2014	8	72	9	70	2.2%	0.85 [0.31, 2.34]	
Schmid 2016	53	92	46	88	5.4%	1.24 [0.69, 2.23]	
Waal 2021	12	246	10	234	2.6%	1.15 [0.49, 2.71]	
Wang 2021	6	66	9	68	2.2%	0.66 [0.22, 1.96]	
Yealy 2014	12	439	11	456	2.8%	1.14 [0.50, 2.60]	
Subtotal (95% CI)	2	2300		2298	66.1%	0.78 [0.65, 0.95]	•
Total events	286		339				
Heterogeneity: Chi <sup>2</sup> = 1	7.04, df = 1	15 (P =	= 0.32); l <sup>2</sup>	² = 12%	, D		
Test for overall effect: 2	Z = 2.53 (P	= 0.0	1)				
1.6.2 non-RCTs							
Jin 2016	32	131	38	101	8.8%	0.54 [0.30, 0.94]	
Kanji 2014	65	95	88	93	7.6%	0.12 [0.05, 0.33]	
Liu 2016	0	48	0	50		Not estimable	
Pan 2019	50	103	47	68	7.9%	0.42 [0.22, 0.80]	
Suzuki 2014	9	53	12	45	2.9%	0.56 [0.21, 1.49]	
Thomson 2014	8	123	28	141	6.6%	0.28 [0.12, 0.64]	
Subtotal (95% CI)		553		498	33.9%	0.37 [0.27, 0.51]	•
Total events	164		213				
Heterogeneity: Chi <sup>2</sup> = 7	7.60, df = 4	(P = 0)	).11); l² =	47%			
Test for overall effect: 2	Z = 6.02 (P	< 0.00	0001)				
Total (95% CI)	2	2853		2796	100.0%	0.64 [0.55, 0.76]	◆
Total events	450		552	2100			•
Heterogeneity: Chi <sup>2</sup> - 3	400 16 df - 1	20 (P	= 0.008\.	$ ^{2} = 10$	0/2		_ <del></del>
Test for overall effect:	7 - 531/D		- 0.000),	- 40	/0		0.05 0.2 1 5 20
Test for subaroun differ	rences: Chi	$^{2} = 15$	10 df =	1 (P < 1	0 0001) 12	= 93.5%	Favours [experimental] Favours [control]

Figure 6. Pooled AKI incidence of subgroup analysis concerning RCTs and non- RCTs. AKI, Acute kidney injury; RCT, randomized controlled trial; M-H, Mantel–Haenszel; CI, confidence interval.

summary, the beneficial effect of GDFT on renal function is more significant in patients without AKI.

We further analyzed the role of fluid administration and vasopressor requirements. The results demonstrated that although GDFT tended to increase fluid administration within the initial six hours compared with usual care, it was not substantially different between the groups in the initial 24 h. After 24 h, fluid administration was less common in the GDFT group. In addition, GDFT was associated with more vasopressor requirements. Using vasopressors for a short duration might meet the acute demand for oxygen delivery and limit the volume of fluid administration [7]. Guidelines recommend that accurate and timely fluid therapy improves organ function [50]. Excessive volume expansion is also associated with adverse outcomes, including renal dysfunction [51-53]. GDFT by means of fluids and vasopressors can minimize the time of low perfusion

and spare unwarranted fluid therapy, which may contribute to the prevention of AKI.

The strengths of this study include broad search strategy, inclusion of extensive studies and the latest research with high quality of methodology. Moreover, unlike previous meta-analyses focused on the effect of goal-directed therapy on AKI in patients undergoing surgery [9], we are the first to focus on critically ill patients. In addition, we further performed sensitivity analysis and subgroup analyses, generating new hints for practical applications. In fact, all critically ill patients were at risk for AKI. GDFT aimed at dynamic parameters may be more helpful for AKI prevention but does not change the disease course.

This study has a number of limitations. First, the protocols of GDFT varied in the included studies, and the definitions of usual care may be different in different areas. This led to relatively high heterogeneity, although the results remained consistent across sensitivity and subgroup analyses. Second, most of the included studies lacked baseline kidney function, that is, chronic kidney disease. Third, the included studies varied in definitions, and timeframes of AKI incidence were another limitation. Last, there may be potential publication bias.

# Conclusions

In conclusion, this meta-analysis suggests that GDFT reduced the incidence of AKI in critical illness, including postoperative and medical patients. Sensitivity analysis enrolling only trials with a low risk of bias and subgroup analysis of RCTs confirmed this result. The reduction was significant in GDFT based on dynamic indicators, rather than EGDT and other protocols. However, there was no difference in RRT support between the groups. Fluid administration seemed to be higher in the GDFT group within the first 6 h but lower after 24 h. Moreover, GDFT was associated with more vasopressor requirements. Prompt, targeted resuscitation combined with fluid and vasopressors may contribute to the prevention of AKI.

#### **Disclosure statement**

The authors report no conflict of interest.

#### Funding

This work was supported by the Health and Family Planning Commission of Hebei Province, China [No: ZD20140134]. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

# ORCID

Chai Zhao (i) http://orcid.org/0000-0002-5073-2766

#### Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article.

#### References

- [1] Choi JG, Kim SY, Jeong M, et al. Pharmacotherapeutic potential of ginger and its compounds in age-related neurological disorders. Pharmacol Ther. 2018;182: 777–69.
- [2] Kellum JA, Chawla LS, Keener C, et al. The effects of alternative resuscitation strategies on acute kidney

injury in patients with septic shock. Am J Respir Crit Care Med. 2016;193(3):281–287.

- [3] Deng Y, Yuan J, Chi R, et al. The incidence, risk factors and outcomes of postoperative acute kidney injury in neurosurgical critically ill patients. Sci Rep. 2017;7(1): 4245.
- [4] Bihorac A, Yavas S, Subbiah S, et al. Long-term risk of mortality and acute kidney injury during hospitalization after major surgery. Ann Surg. 2009;249(5): 851–858.
- [5] Brienza N, Giglio MT, Dalfino L. Protocoled resuscitation and the prevention of acute kidney injury. Curr Opin Crit Care. 2012;18(6):613–622.
- [6] Dalfino L, Giglio MT, Puntillo F, et al. Haemodynamic goal-directed therapy and postoperative infections: earlier is better. A systematic review and meta-analysis. Crit Care. 2011;15(3):R154.
- [7] Cecconi M, Corredor C, Arulkumaran N, et al. Clinical review: goal-directed therapy-what is the evidence in surgical patients? The effect on different risk groups. Crit Care. 2012;17(2):209.
- [8] Brienza N, Giglio MT, Marucci M, et al. Does perioperative hemodynamic optimization protect renal function in surgical patients? A meta-analytic study. Crit Care Med. 2009;37(6):2079–2090.
- [9] Giglio M, Dalfino L, Puntillo F, et al. Hemodynamic goal-directed therapy and postoperative kidney injury: an updated meta-analysis with trial sequential analysis. Crit Care. 2019;23(1):232.
- [10] Lin SM, Huang CD, Lin HC, et al. A modified goaldirected protocol improves clinical outcomes in intensive care unit patients with septic shock: a randomized controlled trial. Shock. 2006;26(6):551–557.
- [11] Rivers E, Nguyen B, Havstad S, et al. Early goaldirected therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368–1377.
- [12] de Oliveira CF, de Oliveira DS, Gottschald AF, et al. ACCM/PALS haemodynamic support guidelines for paediatric septic shock: an outcomes comparison with and without monitoring central venous oxygen saturation. Intensive Care Med. 2008;34(6):1065–1075.
- [13] Ahmed W, Memon JI, Rehmani R, et al. Outcome of patients with acute kidney injury in severe sepsis and septic shock treated with early goal-directed therapy in an intensive care unit. Saudi J Kidney Dis Transpl. 2014;25(3):544–551.
- [14] Yealy DM, Kellum JA, Huang DT, ProCESS Investigators, et al. A randomized trial of protocolbased care for early septic shock. N Engl J Med. 2014; 370(18):1683–1693.
- [15] Amendola CP, Silva JM, Jr Carvalho T, et al. Goaldirected therapy in patients with early acute kidney injury: a multicenter randomized controlled trial. Clinics (Sao Paulo). 2018;73:e327.
- [16] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
- [17] Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

- [18] Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
- [19] Zhuo L, Qian-m ei W, Fan-yang L, et al. Effect of early goal-directed therapy on patients with moderate brain injury and traumatic shock. Clinical Misdiagnosis & Mistherapy. 2016;29:80–83.
- [20] Biao H, Zhang M, Dabi H, et al. Clinical study on the value of early hemodynamic intervention in the management of hypovolemic shock with unknown cause. Journal of Chongqing Medical University. 2018;43: 913–918.
- [21] Pan C, Liu J, Hu X. [Effect of goal-directed therapy bundle based on PiCCO parameters to the prevention and treatment of acute kidney injury in patients after cardiopulmonary bypass cardiac operation: a prospective observational study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019;31(6):731–736.
- [22] Jin Y, Zhao H, Chen Y. Target-directed management strategy reduces complications in high-risk subjects undergoing cardiac and major vascular surgery. Int J Clin Exp Med. 2016;9:22241–22249.
- [23] Douglas IS, Alapat PM, Corl KA, et al. Fluid response evaluation in sepsis hypotension and shock: a randomized clinical trial. Chest. 2020;158(4): 1431–1445.
- [24] Goepfert MS, Richter HP, Zu Eulenburg C, et al. Individually optimized hemodynamic therapy reduces complications and length of stay in the intensive care unit: a prospective, randomized controlled trial. Anesthesiology. 2013;119(4):824–836.
- [25] Investigators A, Group ACT, Peake SL, et al. Goaldirected resuscitation for patients with early septic shock. N Engl J Med. 2014;371(16):1496–1506.
- [26] Jhanji S, Vivian-Smith A, Lucena-Amaro S, et al. Haemodynamic optimisation improves tissue microvascular flow and oxygenation after major surgery: a randomised controlled trial. Crit Care. 2010;14(4):R151.
- [27] Kanji HD, McCallum J, Sirounis D, et al. Limited echocardiography-guided therapy in subacute shock is associated with change in management and improved outcomes. J Crit Care. 2014;29(5):700–705.
- [28] Latham HE, Bengtson CD, Satterwhite L, et al. Stroke volume guided resuscitation in severe sepsis and septic shock improves outcomes. J Crit Care. 2017;42: 42–46.
- [29] Luo J, Xue J, Liu J, et al. Goal-directed fluid restriction during brain surgery: a prospective randomized controlled trial. Ann Intensive Care. 2017;7(1):16.
- [30] MacDonald N, Pearse RM, Murray PT, et al. The role of goal-directed therapy in the prevention of acute kidney injury after major gastrointestinal surgery: substudy of the OPTIMISE trial. Eur J Anaesthesiol. 2019; 36(12):924–932.
- [31] Martin D, Koti R, Gurusamy K, COLT study group, et al. The cardiac output optimisation following liver transplant (COLT) trial: a feasibility randomised controlled trial. HPB (Oxford). 2020;22(8):1112–1120.
- [32] McKendry M, McGloin H, Saberi D, et al. Randomised controlled trial assessing the impact of a nurse delivered, flow monitored protocol for optimisation of

circulatory status after cardiac surgery. BMJ. 2004; 329(7460):258.

- [33] Mouncey PR, Osborn TM, Power GS, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372(14):1301–1311.
- [34] Musikatavorn K, Plitawanon P, Lumlertgul S, et al. Randomized controlled trial of ultrasound-guided fluid resuscitation of sepsis-induced hypoperfusion and septic shock. West J Emerg Med. 2021;22(2):369–378.
- [35] Parke RL, Gilder E, Gillham MJ, et al. A multicenter, open-label, randomized controlled trial of a conservative fluid management strategy compared with usual care in participants after cardiac surgery: the fluids after bypass study. Crit Care Med. 2021;49(3):449–461.
- [36] Pearse RM, Harrison DA, MacDonald N, et al. Effect of a perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: a randomized clinical trial and systematic review. JAMA. 2014;311(21):2181–2190.
- [37] Pestana D, Espinosa E, Eden A, et al. Perioperative goal-directed hemodynamic optimization using noninvasive cardiac output monitoring in major abdominal surgery: a prospective, randomized, multicenter, pragmatic trial: POEMAS study (PeriOperative goal-directed therapy in major abdominal surgery). Anesth Analg. 2014;119(3):579–587.
- [38] Schmid S, Kapfer B, Heim M, et al. Algorithm-guided goal-directed haemodynamic therapy does not improve renal function after major abdominal surgery compared to good standard clinical care: a prospective randomised trial. Crit Care. 2016;20(1):50.
- [39] Suzuki S, Woinarski NC, Lipcsey M, et al. Pulse pressure variation-guided fluid therapy after cardiac surgery: a pilot before-and-after trial. J Crit Care. 2014; 29(6):992–996.
- [40] Thomson R, Meeran H, Valencia O, et al. Goal-directed therapy after cardiac surgery and the incidence of acute kidney injury. J Crit Care. 2014;29(6):997–1000.
- [41] Yu J, Zheng R, Lin H, et al. Global end-diastolic volume index vs CVP goal-directed fluid resuscitation for COPD patients with septic shock: a randomized controlled trial. Am J Emerg Med. 2017;35(1):101–105.
- [42] de Waal EEC, Frank M, Scheeren TWL, et al. Perioperative goal-directed therapy in high-risk abdominal surgery. A multicenter randomized controlled superiority trial. J Clin Anesth. 2021;75:110506.
- [43] Wang K, Sun SL, Wang XY, et al. Bioelectrical impedance analysis-guided fluid management promotes primary fascial closure after open abdomen: a randomized controlled trial. Mil Med Res. 2021;8(1):36.
- [44] Froghi F, Gopalan V, Anastasiou Z, et al. Effect of post-operative goal-directed fluid therapy (GDFT) on organ function after orthotopic liver transplantation: secondary outcome analysis of the COLT randomised control trial. Int J Surg. 2022;99:106265.
- [45] Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813–818.
- [46] Blantz RC. Pathophysiology of pre-renal azotemia. Kidney Int. 1998;53(2):512–523.
- [47] Prowle JR, Bellomo R. Sepsis-associated acute kidney injury: macrohemodynamic and microhemodynamic

alterations in the renal circulation. Semin Nephrol. 2015;35(1):64–74.

- [48] John S. Lessons learned from kidney dysfunction: preventing organ failure. Med Klin Intensivmed Notfmed. 2020;115(Suppl 1):21–27.
- [49] Jiang LB, Zhang M, Jiang SY, et al. Early goal-directed resuscitation for patients with severe sepsis and septic shock: a meta-analysis and trial sequential analysis. Scand J Trauma Resusc Emerg Med. 2016;24:23.
- [50] Liu DW, Wang XT, Zhang HM, et al. Hemodynamic therapy for severe cases—Beijing consensus. Chin J Intern Med. 2015;54:248–271.
- [51] Woodward CW, Lambert J, Ortiz-Soriano V, et al. Fluid overload associates with major adverse kidney events in critically ill patients with acute kidney injury requiring continuous renal replacement therapy. Crit Care Med. 2019;47(9):e753–e60.
- [52] National Heart L, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials N, Wiedemann HP, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24): 2564–2575.
- [53] Grams ME, Estrella MM, Coresh J, et al. Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol. 2011;6(5):966–973.